Gsk (GSK) Net Margin (2009 - 2026)

Gsk (GSK) has 18 years of Net Margin data on file, last reported at 13.54% in Q3 2026.

• For the quarter ending Q3 2026, Net Margin changed N/A year-over-year to 13.54%; the trailing twelve-month figure through Sep 2026 stood at 11.46% (changed N/A YoY), and the FY2025 full-year result was 17.5%, up 929.0% from the prior year.
• Net Margin was 13.54% for Q3 2026 at Gsk, up from 5.17% in the prior quarter.
• In the past five years, Net Margin ranged from a high of 138.22% in Q3 2022 to a low of 0.72% in Q3 2024.
• A 5-year average of 22.9% and a median of 18.07% in 2025 frame the typical range for Net Margin.
• Across the five-year window, Net Margin soared 12059 bps in 2022 and slumped 12025 bps in 2023, its largest moves.
• Gsk's Net Margin stood at 18.7% in 2022, then grew by 18 bps to 22.04% in 2023, then plunged by 34 bps to 14.55% in 2024, then plunged by 35 bps to 9.39% in 2025, then surged by 44 bps to 13.54% in 2026.
• Per Business Quant data, the three most recent Net Margin figures were 13.54% in Q3 2026, 5.17% in Q2 2026, and 22.77% in Q1 2026.